Loading...
XNASANTX
Market cap40mUSD
Jan 07, Last price  
1.35USD
1D
-2.17%
1Q
29.81%
Jan 2017
-97.12%
IPO
-91.22%
Name

AN2 Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ANTX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-65m
L+56.09%
-5,635,000-13,600,000-21,474,000-41,470,000-64,732,000
CFO
-53m
L+59.25%
-2,486,000-5,364,000-20,484,000-33,462,000-53,288,000
Dividend
Jan 11, 20180.65625 USD/sh

Profile

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
URL
https://www.an2therapeutics.com/
IPO date
Mar 25, 2022
Employees
35
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
69,635
42,339
Unusual Expense (Income)
NOPBT
(69,635)
(42,339)
NOPBT Margin
Operating Taxes
514
Tax Rate
NOPAT
(69,635)
(42,853)
Net income
(64,732)
56.09%
(41,470)
93.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
84,529
70,355
BB yield
-17.48%
-38.05%
Debt
Debt current
53
Long-term debt
106
Deferred revenue
Other long-term liabilities
(51)
Net debt
(134,489)
(99,119)
Cash flow
Cash from operating activities
(53,288)
(33,462)
CAPEX
Cash from investing activities
(43,278)
(21,771)
Cash from financing activities
84,994
70,355
FCF
(69,582)
(42,906)
Balance
Cash
107,295
96,059
Long term investments
27,194
3,219
Excess cash
134,489
99,278
Stockholders' equity
(154,180)
12,463
Invested Capital
278,881
82,964
ROIC
ROCE
EV
Common stock shares outstanding
23,600
19,403
Price
20.49
115.01%
9.53
 
Market cap
483,566
161.52%
184,907
 
EV
349,077
188,348
EBITDA
(69,635)
(43,031)
EV/EBITDA
Interest
514
Interest/NOPBT